A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs NT 501 (Primary)
- Indications Retinal telangiectasis
- Focus Registrational; Therapeutic Use
- Sponsors Neurotech USA
- 09 Dec 2019 Planned End Date changed from 31 Mar 2021 to 31 Mar 2022.
- 09 Dec 2019 Planned primary completion date changed from 31 Mar 2021 to 31 Mar 2022.
- 12 Feb 2019 According to a Neurotech Pharmaceuticals (Neurotech USA) media release, two parallel studies (NCT03319849 and NCT03316300) are sponsored by Neurotech in collaboration with the Lowy Medical Research Institute (LMRI).